bullish
Green Cross (006280 KS): Strengthening Base Business; US Entry Remains Key Catalyst
150 Views19 Oct 2022 17:46
SUMMARY
- Green Cross (006280 KS) is seeing gradual recovery in its base business, with the company’s plasma and vaccine businesses are back to double-digit growth path.
- The company is preparing to resubmit marketing application to the FDA for its biologics license application for GC5107, a blood derivative product indicated for the treatment of primary immunodeficiency diseases.
- Green Cross shares are trading at a forward P/E of 20.9x, cheaper than peers. Entry into the lucrative U.S. immunoglobulin market will call for multiple expansion of the shares.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Green Cross (006280 KS): Alyglo Is Accelerating U.S. Market Entry; Base Business Shows Strength24 Sep 2024
- Green Cross (006280 KS): Turns Profitable in Q2; All Eyes on the Maiden US Approval of Blood Product16 Aug 2023
- Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection23 Jun 2022
- Potential Additions & Deletions in MSCI Korea Rebalance in May 202207 Mar 2022
- Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback15 Jan 2022
x